Real‐World Outcomes of Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval
Oncologist - United States
doi 10.1634/theoncologist.2018-0307
Full Text
Open PDFAbstract
Available in full text
Date
December 27, 2018
Authors
Publisher
Alphamed Press